Idorsia Ltd. · SIX:IDIA
Idorsia — Fact Sheet (September 2026)
5 slides from Idorsia's fact sheet, Sep 30, 2026
Slide 1: Financial performance
Financial performance Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize
Slide 2: Financial results
Financial results Net revenue of CHF 172 million in the first Financial overview nine months of 2026 resulted from product sales (CHF 142 million), product sales to in CHF millions, except EPS (CHF) partners (CHF 12 million), and contract and number of shares (millions) Nine Months Third Quarter rev
Slide 3: Liquidity and indebtedness
The US GAAP net loss resulted in a net loss Liquidity and indebtedness per share of CHF (0.80) (basic and diluted) in the first nine months of 2026, compared to Liquidity on September 30, 2026, amounted to CHF 85 million. This amount does not include a net loss per share of CHF (0.17) basic and the
Slide 4: Idorsia Ltd – shares at a glance
Idorsia Ltd – shares at a glance Idorsia Ltd – stock information As of Sep 30, 2026, the company has been Share price development (in CHF) notified of the following shareholdings amounting to 3% or more of the company’s 8 — Idorsia Ltd ordinary share capital: 7 6 Major shareholders* As of Sep 30, 20
Slide 5: Idorsia is an independent biopharmaceutical company
Idorsia is an independent biopharmaceutical company based on science and innovation. The company is specialized in the discovery, development, and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options. It is headquartered in Allschwil/Basel,